{
"id":"mk19_b_en_s7",
"subspecialtyId":"en",
"title":"Calcium and Bone Disorders",
"jsonContent":{
"type":"section",
"id":"mk19_b_en_s7",
"title":{
"__html":"Calcium and Bone Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"8e1b0e",
"children":[
"Calcium and Bone Disorders"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s7_1",
"title":{
"__html":"Calcium Homeostasis and Bone Physiology"
},
"titleNode":{
"type":"section-title",
"hlId":"b5b41c",
"children":[
"Calcium Homeostasis and Bone Physiology"
]
},
"children":[
{
"type":"p",
"hlId":"5ac555",
"children":[
"Regulation of serum calcium level depends on the actions of vitamin D and parathyroid hormone (PTH). The primary effect of vitamin D is to enhance intestinal absorption of calcium, whereas the effects of PTH are mediated through regulation of renal calcium retention and excretion and bone resorption ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f25",
"wrapId":"1",
"children":[
"Figure 25"
]
}
]
},
")"
]
},
". Measured calcium levels depend on the amount bound to albumin, which can be affected by nutrition and acid-base status. When albumin concentration is low, ionized calcium measurement or corrected total calcium calculation is required to accurately assess calcium levels."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_en_f25"
]
},
{
"type":"p",
"hlId":"9a0f96",
"children":[
"Vitamin D is produced in the skin in response to sunlight and is also provided by dietary sources and supplements. Vitamin D activation requires hydroxylation, initially by the liver to 25-hydroxyvitamin D and subsequently by the kidney to the active form of 1,25-dihydroxyvitamin D (calcitriol). 25-Hydroxyvitamin D is the storage form of vitamin D in the body, and its measurement is the most appropriate test to assess vitamin D deficiency."
]
},
{
"type":"p",
"hlId":"ca5d0c",
"children":[
"The initial response to a decline in serum calcium is an increase in PTH secretion, which decreases renal calcium excretion and increases calcium resorption from bone. PTH also induces renal conversion of 25-hydroxyvitamin D to calcitriol, which subsequently increases intestinal calcium absorption. PTH-mediated mobilization of calcium from bone over months to years in response to chronic negative calcium balance can lead to metabolic bone disease."
]
},
{
"type":"p",
"hlId":"e5f957",
"children":[
"In contrast to the response to hypocalcemia, bone and intestinal changes do not significantly contribute to the correction of hypercalcemia. Instead, the renal response predominates with an increased filtered load and suppression of PTH secretion, leading to robust excretion of calcium by the kidneys provided that circulating volume is adequate."
]
},
{
"type":"p",
"hlId":"da3ecd",
"children":[
"In addition to a role in calcium homeostasis, bone resorption and formation also allows for continuous skeletal adaptation and repair; the entire skeleton is remodeled approximately every 10 years. Osteocytes coordinate bone remodeling, which is initiated by osteoclastic resorption and then followed by much slower osteoblastic bone formation, culminating in mineralization of a collagen-protein matrix. Rates of bone resorption and formation can be measured with biochemical markers of bone turnover (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_en_v07",
"wrapId":"2",
"children":[
"Video 7"
]
}
]
},
"). While such markers have been useful in clinical trials to better understand the mechanism of pharmacologic agents, their use in clinical practice is not well defined."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_en_v07"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"d162fc",
"children":[
"The primary effect of vitamin D is to enhance intestinal absorption of calcium, whereas the effects of parathyroid hormone are primarily mediated through regulation of calcium retention and excretion in the kidney."
]
},
{
"type":"keypoint",
"hlId":"e8e1c1",
"children":[
"Measurement of 25-hydroxyvitamin D is the most appropriate test for vitamin D deficiency."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2",
"title":{
"__html":"Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"ca8640",
"children":[
"Hypercalcemia"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s7_2_1",
"title":{
"__html":"Clinical Features of Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"6c3cd9",
"children":[
"Clinical Features of Hypercalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"e5567a",
"children":[
"The incidental finding of asymptomatic hypercalcemia on routine blood tests is common. Classic symptoms of hypercalcemia include polyuria, polydipsia, and nocturia. Additional symptoms may include anorexia, nausea, abdominal pain, constipation, and mental status changes. At higher calcium levels, patients may become obtunded. However, symptoms do not correlate linearly with serum calcium or PTH levels."
]
},
{
"type":"p",
"hlId":"7f2cc0",
"children":[
"Severe hypercalcemia and hypercalciuria can lead to volume depletion and acute kidney injury, nephrolithiasis, or nephrocalcinosis. Skeletal manifestations reflect the underlying cause of hypercalcemia. Primary hyperparathyroidism may present as osteoporosis, and severe disease is associated with bone pain and osteitis fibrosa cystica (a radiographic diagnosis demonstrating widespread subperiosteal bone resorption). In contrast, lytic bone lesions associated with hypercalcemia are often the result of multiple myeloma or breast cancer."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"ddfbd3",
"children":[
"Manifestations of hypercalcemia are variable but may include polyuria, polydipsia, nocturia, anorexia, nausea, abdominal pain, constipation, and mental status changes; acute kidney injury, nephrolithiasis, nephrocalcinosis, and skeletal changes may also occur."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2",
"title":{
"__html":"Causes and Diagnosis of Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"1ebff0",
"children":[
"Causes and Diagnosis of Hypercalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"f34d44",
"children":[
"A thorough history and physical examination is essential in patients with hypercalcemia, as well as a careful review of medications, including supplements. Hypercalcemia is categorized as mild (<12 mg/dL [3 mmol/L]), moderate (12-14 mg/dL [3-3.5 mmol/L]), or severe (>14 mg/dL [3.5 mmol/L]). When hypercalcemia is incidentally noted, repeat measurement is indicated. If hypercalcemia is confirmed, simultaneous measurement of serum calcium and PTH is the next step in categorizing PTH-mediated and non–PTH-mediated hypercalcemia. Ionized calcium measurement is not necessary if serum albumin or corrected total calcium levels are normal or if no acute acid-base disorders are present."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"7b8f4d",
"children":[
"Initial diagnostic testing for hypercalcemia requires simultaneous measurement of serum calcium and parathyroid hormone (PTH), which allows classification as PTH-related and non–PTH-related disease."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_1",
"title":{
"__html":"Medications That Cause Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"d62ca1",
"children":[
"Medications That Cause Hypercalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"066841",
"children":[
"Thiazide diuretics may cause mild hypercalcemia, especially in the setting of previously unrecognized disease. Hypercalcemia associated with lithium therapy is caused by altered PTH secretion and may occur years after initiation of therapy. If possible, stopping the medication and monitoring calcium levels is the first step in management."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_2",
"title":{
"__html":"Parathyroid Hormone–Mediated Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"b6a2f8",
"children":[
"Parathyroid Hormone–Mediated Hypercalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"27e0e4",
"children":[
"PTH secretion decreases abruptly in response to an increase in serum calcium concentration. Therefore, a PTH level that is elevated or inappropriately normal (usually in the upper half of the reference range) in a patient with hypercalcemia is diagnostic of PTH-mediated hypercalcemia ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f26",
"wrapId":"3",
"children":[
"Figure 26"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_en_f26"
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_2_1",
"title":{
"__html":"Primary Hyperparathyroidism"
},
"titleNode":{
"type":"section-title",
"hlId":"304d28",
"children":[
"Primary Hyperparathyroidism"
]
},
"children":[
{
"type":"p",
"hlId":"f4628b",
"children":[
"Primary hyperparathyroidism is typically caused by a solitary parathyroid adenoma. Women are more often affected than men, with a peak incidence in the seventh decade of life. Hypercalcemia is usually mild (within 1 mg/dL [0.25 mmol/L] of the upper limit of normal) and may be intermittently normal. Hypercalciuria is present in up to 30% of patients. Because PTH enhances renal phosphate excretion, low or low-normal serum phosphorus concentrations support the diagnosis."
]
},
{
"type":"p",
"hlId":"2815ec",
"children":[
"Management includes assessment of symptoms, complications, and consideration of surgical or medical intervention."
]
},
{
"type":"p",
"hlId":"e27106",
"children":[
"Symptomatic patients typically undergo surgery. Evaluation should include assessment of kidney function and bone mineral density (BMD) with dual-energy x-ray absorptiometry (DEXA) with imaging of the nondominant distal one-third of the radius, which can be particularly affected in patients with hyperparathyroidism. Although parathyroid imaging with sestamibi or neck ultrasonography may localize an adenoma and help plan surgical intervention, these modalities do not determine if surgery is indicated. In the absence of a history of calcium nephrolithiasis, kidney imaging may be indicated to exclude occult stones if this finding would change management. Changes in specific end points during monitoring that lead to a recommendation for parathyroid surgery include serum calcium level greater than 1 mg/dL (0.25 mmol/L) above the upper limit of normal; changes in kidney function (creatinine clearance <60 mL/min or clinical development of a kidney stone or by imaging); a T-score of less than −2.5 at the lumbar spine, total hip, femoral neck, or distal one-third of the radius, or a significant reduction in BMD; and vertebral fracture by radiography, CT, MRI, or vertebral fracture assessment."
]
},
{
"type":"p",
"hlId":"2887d8",
"children":[
"Medical management includes limiting dietary calcium intake to approximately 1000 mg/day. Measurement of 25-hydroxyvitamin D and cautious correction of vitamin D deficiency is important. Repletion is recommended for patients with levels less than 20 ng/dL (50 nmol/L) with a goal range of 20 to 30 ng/dL (50-75 nmol/L)."
]
},
{
"type":"p",
"hlId":"fb7070",
"children":[
"Surgery results in a 95% cure rate and less than 1% rate of complications with an experienced surgeon. Preoperative correction of vitamin D deficiency is important to minimize postoperative hypocalcemia, which is the result of relative hypoparathyroidism and reduced PTH-mediated production of 1,25-dihydroxyvitamin D. In severe cases, postoperative hypocalcemia may occur in response to a rapid flux of calcium into bone (hungry bone syndrome). Patients with mild primary hyperparathyroidism commonly require calcium supplementation for up to 1 week after parathyroidectomy until residual parathyroid tissue normalizes serum calcium concentrations. Reassessment of BMD 1 year after parathyroidectomy may show improvement in BMD, especially at the spine."
]
},
{
"type":"p",
"hlId":"6a3b51",
"children":[
"Approximately one in three patients with asymptomatic primary hyperparathyroidism who initially defer surgery will develop indications for surgery over 10 to 15 years of observation. In those ineligible or who refuse surgery, management should include annual measurement of serum calcium and creatinine. BMD should be obtained every 2 years, and spine imaging should be considered if the patient has significant loss of height or back pain. A 24-hour urinary calcium excretion measurement is not always required for the diagnosis of primary hyperparathyroidism but helps assess risk of kidney complications in asymptomatic patients. Patients with an elevated PTH level but normal levels of calcium, creatinine, and vitamin D (normocalcemic primary hyperparathyroidism) may be treated similarly to those with asymptomatic primary hyperparathyroidism."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"c06377",
"children":[
"25-Hydroxyvitamin D measurement and cautious vitamin D deficiency correction is important in patients with primary hyperparathyroidism."
]
},
{
"type":"keypoint",
"hlId":"e9b153",
"children":[
"Serum calcium level, skeletal complications, and kidney function determine the choice between surgical and medical management in asymptomatic primary hyperparathyroidism."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_2_2",
"title":{
"__html":"Parathyroid Carcinoma"
},
"titleNode":{
"type":"section-title",
"hlId":"9084ff",
"children":[
"Parathyroid Carcinoma"
]
},
"children":[
{
"type":"p",
"hlId":"2264d5",
"children":[
"Parathyroid carcinoma is very rare, but may present with symptoms of severe hypercalcemia, with serum levels greater than 14 mg/dL (3.5 mmol/L) and markedly high PTH concentrations. The primary treatment is surgical resection. Following surgery, 50% of patients may have residual or recurrent disease. Severe hypercalcemia that is not amenable to surgery can be treated chronically with cinacalcet."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_2_3",
"title":{
"__html":"Tertiary Hyperparathyroidism"
},
"titleNode":{
"type":"section-title",
"hlId":"76bb8b",
"children":[
"Tertiary Hyperparathyroidism"
]
},
"children":[
{
"type":"p",
"hlId":"d40fcd",
"children":[
"In patients with end-stage kidney disease, poorly controlled hypocalcemia and hyperphosphatemia cause long-term secondary hyperparathyroidism that can result in multigland parathyroid hyperplasia. In some cases of secondary hyperparathyroidism, this chronic stimulation of the parathyroid glands can lead to autonomous production of PTH by hyperplastic glands, resulting in eucalcemia and even hypercalcemia. This tertiary hyperparathyroidism is most commonly recognized after kidney transplantation. Cinacalcet treatment usually resolves the hypercalcemia."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_3",
"title":{
"__html":"Genetic Causes of Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"5ef475",
"children":[
"Genetic Causes of Hypercalcemia"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s7_2_2_3_1",
"title":{
"__html":"Familial Hypocalciuric Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"d82feb",
"children":[
"Familial Hypocalciuric Hypercalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"e9a33a",
"children":[
"Familial hypocalciuric hypercalcemia (FHH) is an autosomal dominant condition and the most common type of familial hypercalcemia. Normally, the parathyroid glands and kidney detect serum calcium concentrations through the calcium-sensing receptor (CaSR). In FHH, an inactivating mutation of the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CaSR"
]
},
" gene causes the parathyroid gland to perceive serum calcium concentrations as low, resulting in increased PTH secretion and a higher serum calcium level. Simultaneously, the mutated ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CaSR"
]
},
" in the kidney increases kidney resorption of calcium, leading to paradoxical hypocalciuria in the setting of hypercalcemia. Features suggestive of FHH include mild hypercalcemia since childhood; inappropriately normal or elevated PTH level; low 24-hour urine calcium excretion, especially if calcium-creatinine clearance ratio is less than 0.01; or family history of parathyroidectomy without resolution of hypercalcemia. If clinically ambiguous, most cases can be confirmed by ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CaSR"
]
},
" genetic testing."
]
},
{
"type":"p",
"hlId":"452d14",
"children":[
"FHH is a benign condition because patients do not have sequelae of hypercalcemia. Parathyroidectomy is not indicated because hypercalcemia will not resolve with surgery."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"6f9c6b",
"children":[
"The distinction between primary hyperparathyroidism and familial hypocalciuric hypercalcemia (FHH) can be made by a 24-hour urine collection for calcium and creatinine; FHH is characterized by a calcium-creatinine clearance ratio of less than 0.01."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_3_2",
"title":{
"__html":"Multiple Endocrine Neoplasia Syndrome"
},
"titleNode":{
"type":"section-title",
"hlId":"a15466",
"children":[
"Multiple Endocrine Neoplasia Syndrome"
]
},
"children":[
{
"type":"p",
"hlId":"b61203",
"children":[
"Primary hyperparathyroidism in adolescents and young adults may be a manifestation of multiple endocrine neoplasia syndrome (MEN), predominantly MEN1 and occasionally MEN2A syndromes. If the family history is positive for primary hyperparathyroidism, pituitary tumor, Zollinger-Ellison syndrome, early onset pancreatic neoplasm, pheochromocytoma, or medullary thyroid cancer, MEN screening should be considered. In contrast to sporadic primary hyperparathyroidism, hyperparathyroidism may recur in MEN syndromes and is best managed together with or by an endocrinologist."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_4",
"title":{
"__html":"Non–Parathyroid Hormone-Mediated Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"bcd314",
"children":[
"Non–Parathyroid Hormone-Mediated Hypercalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"467142",
"children":[
"The differential diagnosis of hypercalcemia with suppressed PTH is broad; the history, symptoms, and findings may suggest the underlying cause. PTH is usually undetectable but may be very low (<20 pg/mL [20 ng/L]) if hypercalcemia is mild. Hypercalciuria can be severe and may precede hypercalcemia. In severe hypercalcemia, treatment should commence without delay while awaiting results of laboratory testing."
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_4_1",
"title":{
"__html":"Malignancy-Associated Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"0c910b",
"children":[
"Malignancy-Associated Hypercalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"62eab0",
"children":[
"The most common cause of non–PTH-mediated hypercalcemia is malignancy, and it is typically severe (>14 mg/dL [3.5 mmol/L]). Malignancy-associated hypercalcemia is frequently the result of tumor-produced PTH-related protein, which leads to extensive resorption of bone. Renal cell carcinoma, breast cancer, and squamous cell cancers are associated with PTH-related protein hypercalcemia. In approximately 20% of cases, locally mediated osteolysis from extensive skeletal metastases, typically in multiple myeloma and breast cancer, is the cause. For more information, see ",
{
"type":"cross-reference",
"target":"mk19_a_on_s12_2_2",
"children":[
"MKSAP 19 Oncology"
]
},
"."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_4_2",
"title":{
"__html":"Vitamin D–Dependent Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"dca60d",
"children":[
"Vitamin D–Dependent Hypercalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"613c75",
"children":[
"Vitamin D–dependent hypercalcemia is associated with normal to elevated serum phosphorus levels because vitamin D enhances intestinal absorption of phosphorus and suppressed PTH secretion reduces kidney phosphorus excretion."
]
},
{
"type":"p",
"hlId":"ef9f19",
"children":[
"Vitamin D intoxication from chronic high-dose ingestion of vitamin D (typically >50,000 IU/day in patients without malabsorptive conditions) and increased storage in fat causes protracted hypercalciuria, nephrolithiasis, impaired kidney function, and elevated 25-hydroxyvitamin D levels."
]
},
{
"type":"p",
"hlId":"8c98da",
"children":[
"Unregulated conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D may occur in granulomatous tissue associated with fungal infection, tuberculosis, sarcoidosis, and lymphoma, leading to increased intestinal absorption of calcium. These conditions are associated with an inappropriately normal or frankly elevated 1,25-dihydroxyvitamin D level and suppressed PTH. In the absence of an established diagnosis, chest radiography to diagnose sarcoidosis or lymphoma is a reasonable approach."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_2_4_3",
"title":{
"__html":"Other Causes"
},
"titleNode":{
"type":"section-title",
"hlId":"b8b649",
"children":[
"Other Causes"
]
},
"children":[
{
"type":"p",
"hlId":"31f2d9",
"children":[
"Ingestion of large amounts of calcium, typically from antacid use (e.g., calcium carbonate), especially with coexistent chronic kidney disease, causes milk-alkali syndrome."
]
},
{
"type":"p",
"hlId":"7e6e37",
"children":[
"Severe thyrotoxicosis occasionally causes hypercalcemia or hypercalciuria by increasing bone resorption; Addisonian crisis may also occasionally cause hypercalcemia."
]
},
{
"type":"p",
"hlId":"1b00fc",
"children":[
"Acute prolonged immobilization, as seen in spinal cord injuries, can cause a large efflux of calcium from the skeleton through uncoupled bone remodeling with decreased osteoblastic activity despite increased osteoclastic activity. Patients with primary hyperparathyroidism or skeletal metastases are predisposed to hypercalcemia because of immobilization, as are young patients in whom increased bone remodeling is normal."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_2_3",
"title":{
"__html":"Management of Hypercalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"942258",
"children":[
"Management of Hypercalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"f17e38",
"children":[
"Management depends on the severity of the hypercalcemia. If mild (<12 mg/dL [3 mmol/L]), treatment of the underlying disorder is sufficient. Hospitalization may be needed in patients with acute kidney injury, mental status changes, or calcium levels greater than 12 mg/dL (3 mmol/L). Initial treatment of severe hypercalcemia is aggressive hydration to replete volume loss and increase kidney excretion of calcium. Loop diuretics are not recommended in the absence of kidney failure or volume overload. For the acutely symptomatic patient, subcutaneous calcitonin can be used; however, the drug effect wanes after 48 hours. Long-term management of hypercalcemia may require intravenous bisphosphonate therapy to prevent mobilization of calcium from the skeleton, but requires adequate kidney function. Hypercalcemia of malignancy refractory to bisphosphonate therapy can be treated with denosumab. Glucocorticoids and restriction of calcium and vitamin D intake are uniquely beneficial in vitamin D–dependent hypercalcemia. Hemodialysis is reserved for the treatment of severe hypercalcemia in patients with oliguria."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"aefd6e",
"hvc":true,
"children":[
"Loop diuretics are not recommended in hypercalcemia in the absence of kidney failure or volume overload."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_3",
"title":{
"__html":"Hypocalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"0f8247",
"children":[
"Hypocalcemia"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s7_3_1",
"title":{
"__html":"Clinical Features of Hypocalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"a23898",
"children":[
"Clinical Features of Hypocalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"6d14a5",
"children":[
"Most patients with hypocalcemia are asymptomatic or report intermittent paresthesia of the hands and feet or perioral numbness. Patients with severe hypocalcemia may present with neuromuscular symptoms and signs. Carpopedal spasm with characteristic hand posture (flexion at metacarpophalangeal joints and extension at interphalangeal joints) may be spontaneous or triggered by transient distal limb ischemia during blood pressure assessment. Facial nerve hyperirritability and muscle spasm can be demonstrated by percussion of the facial nerve just anterior to the ear. Importantly, laryngospasm, seizure, myocardial dysfunction, and QT-interval prolongation leading to sudden cardiac death caused by severe hypocalcemia (<7.5 mg/dL [1.9 mmol/L]) can occur without prodromal paresthesia or muscle cramping."
]
},
{
"type":"p",
"hlId":"8af306",
"children":[
"Hypocalcemia and hyperphosphatemia caused by chronic hypoparathyroidism can be associated with cataract formation, basal ganglia calcification, papilledema, and dental enamel hypoplasia."
]
},
{
"type":"p",
"hlId":"476651",
"children":[
"Hypocalcemic disorders in outpatients are typically detected on screening blood tests and are mild, with serum calcium 7.5 to 8.9 mg/dL (1.9-2.2 mmol/L). Hypocalcemia may also be detected during evaluation for fragility fractures or low bone mass."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"28f0ae",
"children":[
"Laryngospasm, seizure, myocardial dysfunction, and QT-interval prolongation leading to sudden cardiac death because of severe hypocalcemia (<7.5 mg/dL [1.9 mmol/L]) can occur without prodromal paresthesia or muscle cramping."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_3_2",
"title":{
"__html":"Causes and Diagnosis of Hypocalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"a15ead",
"children":[
"Causes and Diagnosis of Hypocalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"689466",
"children":[
"Hypocalcemia should be confirmed with a second measurement including assessment of and correction for serum albumin concentrations. Ionized calcium measurement is indicated in the setting of acute alkalosis. The next step is simultaneous measurement of serum calcium, phosphorus, creatinine, and PTH."
]
},
{
"type":"section",
"id":"mk19_b_en_s7_3_2_1",
"title":{
"__html":"Hypoparathyroidism"
},
"titleNode":{
"type":"section-title",
"hlId":"0df45b",
"children":[
"Hypoparathyroidism"
]
},
"children":[
{
"type":"p",
"hlId":"7c0d3a",
"children":[
"Hypoparathyroidism is most commonly caused by inadvertent injury during anterior neck surgery (thyroidectomy, parathyroidectomy, head and neck cancer) and may present within a few hours of surgery. Depending on the extent of injury or resection, surgical hypoparathyroidism may last days to weeks. Permanent hypoparathyroidism may be partial or complete; inappropriately normal PTH levels with concurrent hypocalcemia represents the former, whereas the latter is associated with undetectable serum PTH levels and a higher prevalence of hyperphosphatemia and hypercalciuria."
]
},
{
"type":"p",
"hlId":"cf842a",
"children":[
"Other causes of hypocalcemia associated with insufficient PTH secretion include infiltrative disorders (hemochromatosis or Wilson disease), radiation, autoimmunity, and congenital disorders. Chronic hypocalcemia with inappropriately normal PTH occurring within a family may represent an activating mutation of the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CaSR"
]
},
" gene. Hypomagnesemia, which may occur in malnutrition, alcoholism, and with use of loop diuretics and chronic proton pump inhibitor therapy, causes reversible functional parathyroid hypofunction and must be excluded before a low or inappropriately normal PTH level is attributed to hypoparathyroidism. PTH resistance (pseudohypoparathyroidism) is a rare genetic cause of hypocalcemia."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"27ba2a",
"children":[
"Hypomagnesemia causes reversible functional parathyroid hypofunction and must be excluded before a low or inappropriately normal parathyroid hormone level is attributed to hypoparathyroidism."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_3_2_2",
"title":{
"__html":"Other Causes of Hypocalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"2cfaca",
"children":[
"Other Causes of Hypocalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"3225f0",
"children":[
"Malnutrition or malabsorption of vitamin D and/or calcium may be suspected based on clinical history (bariatric surgery, celiac disease) and confirmed by low serum 25-hydroxyvitamin D level or low 24-hour urine calcium excretion (a proxy indicator of calcium intake and absorption). The most common cause of acquired hypocalcemia is impaired production of 1,25-dihydroxyvitamin D and hyperphosphatemia caused by chronic kidney failure."
]
},
{
"type":"p",
"hlId":"96f47a",
"children":[
"Rhabdomyolysis and tumor lysis syndrome increase serum phosphorus and calcium phosphate binding in the vascular space, causing low ionized calcium."
]
},
{
"type":"p",
"hlId":"f19bfc",
"children":[
"Hungry bone syndrome (rapid flux of calcium into bone after parathyroidectomy for severe primary hyperparathyroidism) and widespread osteoblastic metastases (prostate cancer, breast cancer) can cause hypocalcemia, as can saponification of calcium (and magnesium) in necrotic fat in acute pancreatitis."
]
},
{
"type":"p",
"hlId":"350bcf",
"children":[
"Potent antiresorptive drugs, such as intravenous bisphosphonates and denosumab, can cause severe and protracted hypocalcemia by impairing physiologic efflux of calcium from the skeleton in patients with vitamin D deficiency or chronic kidney disease. Therefore, it is important to assess vitamin D levels and correct deficiency before beginning treatment with an antiresorptive drug."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_3_3",
"title":{
"__html":"Management of Hypocalcemia"
},
"titleNode":{
"type":"section-title",
"hlId":"526e8a",
"children":[
"Management of Hypocalcemia"
]
},
"children":[
{
"type":"p",
"hlId":"485fa0",
"children":[
"Severe hypocalcemia (<7.5 mg/dL [1.9 mmol/L]) requires urgent treatment with intravenous calcium. Slow administration through central intravenous access with electrocardiographic monitoring is preferred. Alternatively, teriparatide, 20 μg twice daily, rapidly eliminates symptoms of hypocalcemia in acute postsurgical hypoparathyroidism (as an off-label indication)."
]
},
{
"type":"p",
"hlId":"e236e0",
"children":[
"Vitamin D supplementation, 1000 to 4000 IU/day, and oral calcium carbonate or calcium citrate, administered as 1 to 3 g/day in divided doses taken with meals, may normalize or sufficiently treat mild or chronic hypocalcemia. Calcitriol is needed in the setting of hypoparathyroidism with undetectable PTH or kidney failure because activation of endogenous 1,25-dihydroxyvitamin D requires both PTH and sufficient kidney function."
]
},
{
"type":"p",
"hlId":"c86ba4",
"children":[
"A reasonable goal for most patients with hypocalcemia is a serum calcium concentration at or just below the normal range without hypercalciuria. Monitoring of urine calcium excretion is mandatory because hypercalciuria often limits therapy. Thiazide diuretics are commonly used because they decrease urine calcium excretion. Correction of coexisting hypomagnesemia is also required. Initial treatment of hyperphosphatemia is reduction of dietary phosphorus but occasionally requires the addition of oral phosphate binders if serum phosphorus exceeds the normal range. Recombinant human PTH is available for patients in whom treatment goals are not met with calcium and calcitriol therapy alone."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"16065c",
"children":[
"The goal of therapy for most patients with hypocalcemia is a serum calcium concentration at or just below the normal range without hypercalciuria."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4",
"title":{
"__html":"Metabolic Bone Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"6897da",
"children":[
"Metabolic Bone Disease"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s7_4_1",
"title":{
"__html":"Low Bone Mass and Osteoporosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6797c",
"children":[
"Low Bone Mass and Osteoporosis"
]
},
"children":[
{
"type":"p",
"hlId":"c01ce3",
"children":[
"Bone mass, mineral content, and macro- and microarchitecture determine bone strength. BMD reflects bone mass and mineral content and, in older adults, predicts deterioration of microarchitecture. This relationship and epidemiologic data support the use of BMD determined by DEXA to diagnose low bone mass and assess fracture risk in older adults."
]
},
{
"type":"p",
"hlId":"2b249c",
"children":[
"Fragility fractures (those occurring with the equivalent of a fall from a standing height or less) after age 50 years indicate low bone strength and define clinical osteoporosis, regardless of BMD. Skull, cervical spine, ankle, feet, and hand fractures cannot, by definition, be fragility fractures."
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_1",
"title":{
"__html":"Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"34686e",
"children":[
"Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"edcd75",
"children":[
"Low bone mass in adults may represent poor bone formation, bone loss, or both. Factors that can affect peak bone mass formation include genetic conditions, lifestyle factors, and poor childhood health. Net loss of bone mass can occur in adults when osteoclastic bone resorption exceeds osteoblastic bone formation. The list of risk factors for low bone mass and osteoporosis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t44",
"wrapId":"4",
"children":[
"Table 44"
]
}
]
}
]
},
" and ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t45",
"wrapId":"4",
"children":[
"Table 45"
]
}
]
},
")"
]
},
" is extensive. Some patients, however, have osteoporosis secondary to another disease."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_en_t44",
"mk19_b_en_t45"
]
},
{
"type":"p",
"hlId":"1276d5",
"children":[
"Glucocorticoids are a well-recognized cause of significant bone loss, and risk is increased in older patients, larger doses, and longer duration of therapy. Patients taking glucocorticoids should be on the lowest dose possible for the shortest duration necessary."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_2",
"title":{
"__html":"Screening for Osteoporosis"
},
"titleNode":{
"type":"section-title",
"hlId":"0e2199",
"children":[
"Screening for Osteoporosis"
]
},
"children":[
{
"type":"p",
"hlId":"2c7da9",
"children":[
"Guidelines recommend screening average-risk postmenopausal women with BMD measurement beginning at age 65 years. Guidelines vary in recommendations for routine screening for osteoporosis in men. In premenopausal women and men aged 50 years or younger without risk factors, assessment of BMD for fracture risk is not recommended. Furthermore, otherwise-healthy patients who have BMD results that are below the age- and gender-matched averages (Z-score <0) generally do not require further evaluation or serial monitoring."
]
},
{
"type":"p",
"hlId":"3d92b5",
"children":[
"Patients with risk factors for low bone mass or osteoporosis; fragility fractures of the femur, vertebra ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f27",
"wrapId":"5",
"children":[
"Figure 27"
]
}
]
},
")"
]
},
", pelvis, humerus, or radius; height loss of 4 cm (1.6 in) or more; or kyphosis, should have BMD testing earlier than standard screening recommendations. The American College of Rheumatology recommends that patients anticipated to be receiving long-term glucocorticoid treatment (prednisone at ≥2.5 mg/day for ≥3 months) should have a baseline clinical risk assessment for osteoporosis within 3 to 6 months of initiation of therapy. Specifically, BMD testing is recommended as soon as possible or within 6 months of starting long-term glucocorticoid therapy in adults aged 40 years and older and in adults younger than 40 years with risk factors for osteoporosis or a history of fragility fractures. BMD may also be indicated when fracture risk is elevated based on the results of risk assessment tools such as the Simple Calculated Osteoporosis Risk Estimation, Osteoporosis Self-Assessment Tool, the Osteoporosis Risk Assessment Instrument, and Fracture Risk Assessment Tool. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t46",
"wrapId":"5",
"children":[
"Table 46"
]
}
]
},
" lists recommendations for BMD testing and vertebral imaging."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_en_f27",
"mk19_b_en_t46"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"649ee2",
"children":[
"Guidelines recommend screening for osteoporosis with bone mineral density measurement in average-risk postmenopausal women beginning at age 65 years; screening recommendations for men vary by organization."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_3",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"5f6cc2",
"children":[
"In postmenopausal women and men older than 50 years, the diagnosis of osteopenia is determined by BMD testing (T-score between −1 and −2.5) alone. Osteoporosis in these groups can be diagnosed by BMD testing or clinically. Without secondary causes of low BMD, osteoporosis is diagnosed when the femur neck, total hip, or composite (two or more diagnostic vertebrae) lumbar spine T-score is −2.5 or less, as defined by the World Health Organization. If hip or spine cannot be accurately measured by BMD, DEXA of the distal third of the radius can be used. The clinical diagnosis of osteoporosis is based on the presence of fragility fractures, especially hip or vertebral compression fracture."
]
},
{
"type":"p",
"hlId":"b5759e",
"children":[
"Diagnosis of osteoporosis in premenopausal women and men younger than 50 years can be made with diagnosis of a fragility fracture by recurrent low-energy fractures and low bone mass on DEXA defined by a Z-score less than −2, which indicates “low bone mass for age.” BMD measurement is not indicated in premenopausal women in the absence of recurrent low-energy fractures."
]
},
{
"type":"p",
"hlId":"e654ca",
"children":[
"BMD assessment by quantitative calcaneal ultrasonography or peripheral DEXA may be used to screen for osteoporosis, but abnormal results require confirmation by central DEXA. Quantitative CT provides a DEXA equivalent T-score, is not hindered by degenerative changes in the lumbar spine, and is highly sensitive for detection of vertebral compression fractures; however, because the cost and radiation exposure are greater it is not recommended for osteoporosis screening."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f31cb4",
"children":[
"In postmenopausal women and men older than 50 years, osteoporosis can be diagnosed clinically based on fragility fractures or a bone mineral density T-score of −2.5 or less."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_4",
"title":{
"__html":"Evaluation of Secondary Causes of Low Bone Mass"
},
"titleNode":{
"type":"section-title",
"hlId":"1311ac",
"children":[
"Evaluation of Secondary Causes of Low Bone Mass"
]
},
"children":[
{
"type":"p",
"hlId":"0077c1",
"children":[
"Nonmodifiable factors are the most common cause of low bone mass, but all patients should have a thorough history and physical examination and additional testing based on findings (see ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t44",
"wrapId":"6",
"children":[
"Table 44"
]
}
]
},
", ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t45",
"wrapId":"6",
"children":[
"Table 45"
]
}
]
},
", and ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t46",
"wrapId":"6",
"children":[
"Table 46"
]
}
]
},
")"
]
},
". Although BMD may not be required in all patients to diagnose osteoporosis, its measurement may be helpful to determine whether additional testing is needed and to guide treatment. Testing for secondary causes is summarized in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t47",
"wrapId":"6",
"children":[
"Table 47"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_en_t44",
"mk19_b_en_t45",
"mk19_b_en_t46",
"mk19_b_en_t47"
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_4_1",
"title":{
"__html":"Osteomalacia"
},
"titleNode":{
"type":"section-title",
"hlId":"f8aa27",
"children":[
"Osteomalacia"
]
},
"children":[
{
"type":"p",
"hlId":"355f44",
"children":[
"Osteomalacia is most commonly caused by severe and prolonged vitamin D deficiency. The resultant low concentrations of calcium and phosphate in the bone prevent adequate mineralization of newly formed bone matrix. Unlike osteoporosis, osteomalacia does not result in permanent loss of bone structure. A period of months to years of disordered mineralization is required before bone strength is compromised."
]
},
{
"type":"p",
"hlId":"2e7dcc",
"children":[
"Symptoms of osteomalacia include diffuse bone pain, bone tenderness to palpation (tibial plateau and sternum), and proximal muscle weakness; however, early osteomalacia may present only with low bone mass on DEXA and can be indistinguishable from osteoporosis without further testing. Very low BMD (Z-score ≤−2), low or low-normal serum calcium and phosphorus levels, very low 25-hydroxyvitamin D (<10 ng/mL [25 nmol/L]) level, and secondary hyperparathyroidism help distinguish osteomalacia from osteoporosis. Elevated serum alkaline phosphatase level is particularly suggestive of osteomalacia, although mild elevation can be seen with recent osteoporotic fracture. In severe osteomalacia, radiographs may display an unusual fracture distribution ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f28",
"wrapId":"7",
"children":[
"Figure 28"
]
}
]
},
")"
]
},
". When bone pain in the setting of suspected osteomalacia is not explained by conventional radiographic findings, imaging with radionuclide bone scan or MRI may reveal fractures."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_en_f28"
]
},
{
"type":"p",
"hlId":"b4e482",
"children":[
"The goal of treatment is to normalize serum 25-hydroxyvitamin D (>20 ng/mL [50 nmol/L]), calcium, and phosphorus concentrations with vitamin D supplementation. The skeletal response to treatment is reflected by gradual normalization of alkaline phosphatase level and symptom relief. Resolution may take as long as 12 months; subsequent BMD testing will show significant increases in or normalization of BMD."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_4_2",
"title":{
"__html":"Other Causes"
},
"titleNode":{
"type":"section-title",
"hlId":"b8b649",
"children":[
"Other Causes"
]
},
"children":[
{
"type":"p",
"hlId":"f9b7ac",
"children":[
"Low bone mass and fragility fractures in young and middle-aged adults may result from genetic disorders (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t44",
"wrapId":"8",
"children":[
"Table 44"
]
}
]
},
")"
]
},
". Patients with mild (type 1) osteogenesis imperfecta may present with a history of childhood fractures that decrease in frequency as adults. Hypermobility raises suspicion for Ehlers-Danlos syndrome and related syndromes. Hypophosphatasia should be suspected in middle-aged patients with fractures and serum alkaline phosphatase levels well below the reference range."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_en_t44"
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_5",
"title":{
"__html":"Nonpharmacologic Management"
},
"titleNode":{
"type":"section-title",
"hlId":"025efc",
"children":[
"Nonpharmacologic Management"
]
},
"children":[
{
"type":"p",
"hlId":"22fc71",
"children":[
"Exercise involving weight-bearing, resistance, and balance is important for bone health and may reduce fracture risk at any age, but especially in patients older than 65 years."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_6",
"title":{
"__html":"Pharmacologic Management"
},
"titleNode":{
"type":"section-title",
"hlId":"e9e77a",
"children":[
"Pharmacologic Management"
]
},
"children":[
{
"type":"p",
"hlId":"b94fe0",
"children":[
"The U.S. National Osteoporosis Foundation recommends pharmacologic treatment for patients with osteoporosis-related hip or spine fractures, those with a BMD T-score of −2.5 or less, and those with a BMD T-score between −1 and −2.5 and a 10-year risk for hip fracture of 3% or greater or risk for major osteoporosis-related fracture of 20% or greater as estimated by the Fracture Risk Assessment Tool. Some studies suggest that different thresholds for treatment initiation should be considered in other at-risk populations."
]
},
{
"type":"p",
"hlId":"58a384",
"children":[
"Pharmacotherapy may also be used to prevent loss of BMD in postmenopausal women at risk of osteoporosis and to prevent or treat glucocorticoid-induced osteoporosis. FDA-approved drugs for treatment of osteoporosis and options for prevention are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t48",
"wrapId":"9",
"children":[
"Table 48"
]
}
]
},
". Estrogen therapy is no longer considered first-line therapy for prevention of osteoporosis."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_en_t48"
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_6_1",
"title":{
"__html":"Bisphosphonates"
},
"titleNode":{
"type":"section-title",
"hlId":"f9e152",
"children":[
"Bisphosphonates"
]
},
"children":[
{
"type":"p",
"hlId":"c0b169",
"children":[
"The oral bisphosphonates, alendronate and risedronate, reduce the risk for spine, hip, and nonvertebral fractures and are generally first-line treatment for osteoporosis in postmenopausal women and men older than 50 years. Ibandronate has only shown efficacy in reducing vertebral fractures and is not first-line therapy. In glucocorticoid-induced osteoporosis with moderate to high fracture risk, oral bisphosphonates are recommended as first-line therapy in adult men and women regardless of age."
]
},
{
"type":"p",
"hlId":"f5b740",
"children":[
"Intravenous zoledronic acid once annually is an option if patients experience upper gastrointestinal symptoms or have difficulty taking oral bisphosphonates as directed. An acute-phase response reaction including pyrexia and myalgia may occur after first administration of zoledronic acid in one third of patients but does not typically recur. Zoledronic acid administered every 18 months for 6 years reduces risk of vertebral and nonvertebral fracture in women with osteopenia, an effect not shown with other bisphosphonates."
]
},
{
"type":"p",
"hlId":"408f24",
"children":[
"All bisphosphonates are contraindicated in patients with reduced kidney function (glomerular filtration rate <35 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
") and should not be given until vitamin D deficiency and hypocalcemia are treated, if present."
]
},
{
"type":"p",
"hlId":"6808e6",
"children":[
"Rare adverse effects of antiresorptive agents are osteonecrosis of the jaw and atypical femur fracture. Osteonecrosis of the jaw may occur at any point in therapy, whereas the risk for atypical femur fracture appears to increase with duration of therapy. For most patients, the benefits in reduction of osteoporotic fractures far outweigh the risk of these uncommon adverse effects. In most patients, a drug holiday can be initiated after 3 years (intravenous) to 5 years (oral) of bisphosphonate treatment. Although the best means of patient selection for extended therapy are uncertain, patients remaining at high risk of fracture may continue bisphosphonate treatment or switch to an alternative medication. Similarly, no data are available to guide the duration of the drug holiday, but factors to consider include the bisphosphonate used and whether BMD is maintained on DEXA testing."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"97cb4d",
"children":[
"Bisphosphonates are generally the first-line treatment of osteoporosis; only alendronate and risedronate reduce the risk for spine, hip, and nonvertebral fractures."
]
},
{
"type":"keypoint",
"hlId":"7b4fba",
"children":[
"A drug holiday can be considered in postmenopausal women who are not at high fracture risk after 3 years (intravenous) to 5 years (oral) of bisphosphonate treatment."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_6_2",
"title":{
"__html":"Calcium and Vitamin D Supplementation"
},
"titleNode":{
"type":"section-title",
"hlId":"6a52a2",
"children":[
"Calcium and Vitamin D Supplementation"
]
},
"children":[
{
"type":"p",
"hlId":"8a5997",
"children":[
"Calcium and vitamin D were universally supplemented in osteoporosis pharmacotherapy trials that sought to achieve 25-hydroxyvitamin D levels of 20 to 30 ng/mL (50-75 nmol/L). Although the measurable treatment effect may be small, the National Academy of Medicine recommends calcium intake of 1000 to 1200 mg/day, ideally from dietary sources. A calcium supplement may be used for patients whose diets are insufficient but should not be recommended independent of dietary assessment and intervention. A vitamin D supplement of 1000 IU/day may also be appropriate in the context of osteoporosis care."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_6_3",
"title":{
"__html":"Receptor Activator of Nuclear Factor KB Ligand Inhibitors"
},
"titleNode":{
"type":"section-title",
"hlId":"9e3540",
"children":[
"Receptor Activator of Nuclear Factor KB Ligand Inhibitors"
]
},
"children":[
{
"type":"p",
"hlId":"31327b",
"children":[
"Denosumab is a monoclonal antibody that inhibits osteoclast activation. When administered subcutaneously twice yearly, denosumab suppresses bone resorption, increases bone density, and reduces the incidence of osteoporotic fractures in men and women. Optimal duration of denosumab is uncertain, but fracture risk may be reassessed after 5 to 10 years of therapy. The effects of denosumab are not sustained when treatment is stopped, and alternative antiresorptive therapy, typically an oral bisphosphonate, should be initiated 6 months after the last treatment with denosumab. Denosumab may be preferred in patients with stage 4 chronic kidney disease and in those intolerant of or incompletely responding to bisphosphonate therapy. Adverse effects include hypocalcemia, especially in older patients with vitamin D deficiency or chronic kidney disease, and an increased rate of cellulitis and bronchitis. Medication-related osteonecrosis of the jaw and atypical femur fracture have also been reported with denosumab."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_6_4",
"title":{
"__html":"Anabolic Agents"
},
"titleNode":{
"type":"section-title",
"hlId":"d9d0dd",
"children":[
"Anabolic Agents"
]
},
"children":[
{
"type":"p",
"hlId":"ede7a1",
"children":[
"The anabolic agents teriparatide and abaloparatide stimulate bone formation. Teriparatide (recombinant human PTH [1-34]) is approved for use in postmenopausal women and men or women with glucocorticoid-induced osteoporosis who are at high risk of osteoporotic fracture. It is also used to improve bone mass in men with primary or hypogonadism-related osteoporosis at high risk of fracture. Abaloparatide (recombinant human PTH-related protein [1-34]) is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Both agents require daily subcutaneous injection. Treatment should be limited to 2 years. Improvement in BMD is most evident at the spine. To prevent the loss of newly formed bone, sequential therapy with an antiresorptive agent must begin within 1 month of completing the course of anabolic treatment."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_6_5",
"title":{
"__html":"Sclerostin Inhibitors"
},
"titleNode":{
"type":"section-title",
"hlId":"a6a4ab",
"children":[
"Sclerostin Inhibitors"
]
},
"children":[
{
"type":"p",
"hlId":"fa2623",
"children":[
"Sclerostin is an inhibitor of bone formation produced by osteocytes. Romosozumab is a monoclonal antibody inhibitor of sclerostin that increases bone formation and reduces bone resorption. Monthly subcutaneous injection of romosozumab for 1 year increases spine and hip bone density and reduces the risk for vertebral and nonvertebral fractures in postmenopausal women. Romosozumab may rarely cause osteonecrosis of the jaw or atypical femur fractures. A 1-year course of romosozumab must be followed by a bisphosphonate or denosumab. Because romosozumab may increase the risk of stroke, myocardial infarction, or cardiovascular death, it is contraindicated in patients at increased risk for vascular events."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_6_6",
"title":{
"__html":"Selective Estrogen Receptor Modulators"
},
"titleNode":{
"type":"section-title",
"hlId":"fb8c11",
"children":[
"Selective Estrogen Receptor Modulators"
]
},
"children":[
{
"type":"p",
"hlId":"12b0b9",
"children":[
"Raloxifene and bazedoxifene have tissue-specific estrogen receptor effects, acting as agonists in bone and antagonists in breast and uterus. Because these agents are less effective in fracture prevention than bisphosphonates and may increase the risk of venous thromboembolic disease and stroke, they are not first-line therapy for osteoporosis. Raloxifene reduces the risk of invasive breast cancer and may be most useful in women at high risk for breast cancer. Bazedoxifene is available in combination with conjugated estrogens and prevents hot flashes and bone loss but has not been shown to reduce the risk of fracture."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_1_7",
"title":{
"__html":"Follow-up of Patients With Low Bone Mass"
},
"titleNode":{
"type":"section-title",
"hlId":"02536b",
"children":[
"Follow-up of Patients With Low Bone Mass"
]
},
"children":[
{
"type":"p",
"hlId":"1256fe",
"children":[
"Routine serial DEXA measurements of BMD are not indicated for follow-up of patients at low risk who do not have osteoporosis; subsequent testing depends on baseline BMD. Repeating after 15 years may be reasonable if the hip T-score is normal (>−1) with a 3- to 5-year interval for a T-score between −1 and −2. Retesting at 2 years may be considered if the hip T-score is −2 to −2.4."
]
},
{
"type":"p",
"hlId":"4a68c0",
"children":[
"Repeating BMD testing in patients taking antiresorptive agents may be considered to detect treatment failure. Declining BMD, indicated by a statistically significant percent decrease in g/cm",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" of bone (not by declining T-scores) or a fracture while undergoing treatment, raises concern for an unrecognized secondary cause, nonadherence, or an insufficient response that necessitates reevaluation. The American College of Physicians, however, recommends against monitoring of BMD during treatment because data from several studies showed that women treated with antiresorptive treatment benefited from reduced fractures even if BMD did not increase. Instead, follow-up management should include review of indications for treatment, monitoring of adherence, and reinforcement of lifestyle measures to prevent fractures, minimize bone loss, and avoid frailty."
]
},
{
"type":"p",
"hlId":"67e448",
"children":[
"Drug holiday from bisphosphonate therapy usually involves measurement of BMD to establish a baseline and repeated measurement in 2 to 3 years. Although this approach ostensibly informs subsequent treatment decisions, it has not been validated."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_2",
"title":{
"__html":"Vitamin D Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"2fa8f7",
"children":[
"Vitamin D Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"edbd81",
"children":[
"The most appropriate test to assess adequacy of vitamin D is measurement of serum 25-hydroxyvitamin D. A level of at least 20 ng/mL (50 nmol/L) is recommended to prevent metabolic bone disease in otherwise healthy populations and generally can be met with an intake of 600 to 800 IU/day. Routine screening for vitamin D deficiency is not recommended in healthy populations; however, testing for deficiency is appropriate in groups at high risk or in patients with low bone mass, fragility fractures, hypocalcemia, or hyperparathyroidism. Treatment options for prevention and treatment of vitamin D deficiency vary by indication and underlying disease ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t49",
"wrapId":"10",
"children":[
"Table 49"
]
}
]
},
")"
]
},
". Daily dosing is preferred for maintenance therapy because larger, intermittent doses have been associated with increased risk of falls and fractures. Once replete, maintenance of vitamin D stores may be guided by 25-hydroxyvitamin D levels obtained 3 months after initiation of treatment."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_en_t49"
]
},
{
"type":"p",
"hlId":"ee341d",
"children":[
"A proliferation of scientific publications has associated vitamin D levels with extraskeletal health outcomes. However, intervention trials have not demonstrated a benefit of vitamin D supplementation on most disease outcomes, suggesting that low 25-hydroxyvitamin D levels may be a marker rather than a cause of disease."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"0210d4",
"hvc":true,
"children":[
"Routine screening for vitamin D deficiency is not recommended in healthy populations."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_4_3",
"title":{
"__html":"Paget Disease of Bone"
},
"titleNode":{
"type":"section-title",
"hlId":"a81231",
"children":[
"Paget Disease of Bone"
]
},
"children":[
{
"type":"p",
"hlId":"f66088",
"children":[
"Although Paget disease of bone may present with localized symptoms, it is most commonly diagnosed in asymptomatic older patients presenting with elevated alkaline phosphatase levels or incidental radiographic findings. Commonly affected bones include the skull, spine, sacrum, pelvis, femur, and tibia. Involvement of weight-bearing bones of the lower extremity may result in bone pain, deformity, or fracture. Involvement of a bone approximating a joint can contribute to degenerative joint disease. Expansion of pagetic bone of the upper spine or skull base may cause spinal cord or cranial nerve compression."
]
},
{
"type":"p",
"hlId":"de2aeb",
"children":[
"Diagnosis is based on radiographic findings of thickening of cortical bone, coarsened trabecular markings, and distortion and expansion of involved bone ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f29",
"wrapId":"11",
"children":[
"Figure 29"
]
}
]
},
")"
]
},
". Biopsy is rarely needed. Serum alkaline phosphatase, a marker of increased bone formation, is generally elevated but may be normal in long-term metabolically inactive disease. Patients with suspected Paget disease of bone require assessment of serum calcium, 25-hydroxyvitamin D, and a whole-body radionuclide bone scan. If the bone scan reveals other skeletal sites suspicious for this disease, radiography of those sites is required for further evaluation."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_en_f29"
]
},
{
"type":"p",
"hlId":"c42f2c",
"children":[
"Management of Paget disease is based on symptoms, location of involvement, and disease activity. Indications for treatment include bone pain; risk for fracture and progressive deformity that may compromise bone, joint, or neurologic function; and possibly elevated alkaline phosphatase concentrations. A single dose of 5 mg of intravenous zoledronic acid often achieves the treatment goal of reducing pain and normalizing alkaline phosphatase for up to 5 years."
]
},
{
"type":"p",
"hlId":"591782",
"children":[
"Alkaline phosphatase levels should be monitored annually. Retreatment is indicated if previously normalized levels of alkaline phosphatase exceed normal levels. Involved areas may rarely undergo sarcomatous transformation. If alkaline phosphatase levels or symptoms increase significantly, imaging is required."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"ef05de",
"children":[
"Although Paget disease of bone may present with localized symptoms, diagnosis is most common in asymptomatic older patients presenting with elevated alkaline phosphatase levels or incidental radiographic findings."
]
},
{
"type":"keypoint",
"hlId":"edf5ab",
"children":[
"Indications for treatment of Paget disease include bone pain; risk for fracture and progressive deformity that may compromise bone, joint, or neurologic function; and possibly increased alkaline phosphatase concentrations."
]
},
{
"type":"keypoint",
"hlId":"9863dd",
"children":[
"A single dose of intravenous zoledronic acid often achieves the treatment goal of reducing pain and normalizing alkaline phosphatase in patients with Paget disease of bone."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s7_5",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med. 2018;379:2547-2556. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30586507",
"target":"_blank"
},
"children":[
"PMID: 30586507"
]
},
" doi:10.1056/NEJMcp1800214"
]
},
{
"type":"reference",
"children":[
"Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104:1595-1622. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30907953",
"target":"_blank"
},
"children":[
"PMID: 30907953"
]
},
" doi:10.1210/jc.2019-00221"
]
},
{
"type":"reference",
"children":[
"Curry SJ, Krist AH, Owens DK, et al; US Preventive Services Task Force. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319:2521-2531. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29946735",
"target":"_blank"
},
"children":[
"PMID: 29946735"
]
},
" doi:10.1001/jama.2018.7498"
]
},
{
"type":"reference",
"children":[
"Ensrud KE, Crandall CJ. Osteoporosis. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201708010",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2017;167:ITC17-ITC32. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28761958",
"target":"_blank"
},
"children":[
"PMID: 28761958"
]
}
]
},
{
"type":"reference",
"children":[
"Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med. 2019;380:1738-1747. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31042826",
"target":"_blank"
},
"children":[
"PMID: 31042826"
]
},
" doi:10.1056/NEJMcp1800213"
]
},
{
"type":"reference",
"children":[
"Grossman DC, Curry SJ, Owens DK, et al; US Preventive Services Task Force. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;319:1592-1599. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29677309",
"target":"_blank"
},
"children":[
"PMID: 29677309"
]
},
" doi:10.1001/jama.2018.3185"
]
},
{
"type":"reference",
"children":[
"Insogna KL. Primary hyperparathyroidism. N Engl J Med. 2018;379:1050-1059. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30207907",
"target":"_blank"
},
"children":[
"PMID: 30207907"
]
},
" doi:10.1056/NEJMcp1714213"
]
},
{
"type":"reference",
"children":[
"Qaseem A, Forciea MA, McLean RM, et al; Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M15-1361",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2017;166:818-839. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28492856",
"target":"_blank"
},
"children":[
"PMID: 28492856"
]
}
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_en_t44":{
"id":"mk19_b_en_t44",
"number":44,
"bookId":"en",
"title":{
"__html":"Risk Factors for Low Bone Density and Osteoporosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"def9be",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 44. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t44"
}
]
},
"Risk Factors for Low Bone Density and Osteoporosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"23583d",
"class":"col hd l",
"children":[
"Lifestyle/Modifiable"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f9a2e",
"class":"col hd l",
"children":[
"Non-Modifiable"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f1559",
"class":"col hd l",
"children":[
"Medications/Supplements"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"048f2d",
"class":"cell txt l",
"children":[
"Alcohol use"
]
},
" ",
{
"type":"p",
"hlId":"74afcd",
"class":"cell txt l",
"children":[
"Immobilization (temporary)"
]
},
" ",
{
"type":"p",
"hlId":"6f46cc",
"class":"cell txt l",
"children":[
"BMI <17"
]
},
" ",
{
"type":"p",
"hlId":"76e4e3",
"class":"cell txt l",
"children":[
"Low calcium intake"
]
},
" ",
{
"type":"p",
"hlId":"759f43",
"class":"cell txt l",
"children":[
"Smoking"
]
},
" ",
{
"type":"p",
"hlId":"7001ea",
"class":"cell txt l",
"children":[
"Vitamin D deficiency"
]
},
" ",
{
"type":"p",
"hlId":"8cd84a",
"class":"cell txt l",
"children":[
"Weight loss"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c50b7e",
"class":"cell txt l",
"children":[
"Race/Ethnicity"
]
},
" ",
{
"type":"p",
"hlId":"9d8d2d",
"class":"cell txt l",
"children":[
"Age"
]
},
" ",
{
"type":"p",
"hlId":"daab80",
"class":"cell txt l",
"children":[
"Sex"
]
},
" ",
{
"type":"p",
"hlId":"ea754c",
"class":"cell txt l",
"children":[
"Immobilization (permanent)"
]
},
" ",
{
"type":"p",
"hlId":"4cac6c",
"class":"cell txt l",
"children":[
"First-degree relative with low BMD"
]
},
" ",
{
"type":"p",
"hlId":"59771d",
"class":"cell txt l",
"children":[
"Genetic"
]
},
" ",
{
"type":"p",
"hlId":"281637",
"class":"cell txt li",
"children":[
"Cystic fibrosis"
]
},
" ",
{
"type":"p",
"hlId":"939ed4",
"class":"cell txt li",
"children":[
"Hypophosphatasia"
]
},
" ",
{
"type":"p",
"hlId":"d1a700",
"class":"cell txt li",
"children":[
"Ehlers-Danlos syndrome"
]
},
" ",
{
"type":"p",
"hlId":"dc2deb",
"class":"cell txt li",
"children":[
"Osteogenesis imperfecta"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32f975",
"class":"cell txt l",
"children":[
"Androgen deprivation therapy"
]
},
" ",
{
"type":"p",
"hlId":"bc103e",
"class":"cell txt l",
"children":[
"Anticonvulsants"
]
},
" ",
{
"type":"p",
"hlId":"cea549",
"class":"cell txt l",
"children":[
"Antiretroviral therapy (tenofovir)"
]
},
" ",
{
"type":"p",
"hlId":"6f57b1",
"class":"cell txt l",
"children":[
"Aromatase inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"269ba8",
"class":"cell txt l",
"children":[
"Calcineurin inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"b0ec36",
"class":"cell txt l",
"children":[
"Depo-medroxyprogesterone"
]
},
" ",
{
"type":"p",
"hlId":"d875fb",
"class":"cell txt l",
"children":[
"Glucocorticoids (≥2.5 mg/day prednisone or equivalent for ≥3 months)"
]
},
" ",
{
"type":"p",
"hlId":"800101",
"class":"cell txt l",
"children":[
"GnRH agonists"
]
},
" ",
{
"type":"p",
"hlId":"502a85",
"class":"cell txt l",
"children":[
"Proton pump inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"394da1",
"class":"cell txt l",
"children":[
"Thiazolidinediones"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"BMD = bone mineral density; GnRH = gonadotropin-releasing hormone."
]
]
},
"mk19_b_en_t45":{
"id":"mk19_b_en_t45",
"number":45,
"bookId":"en",
"title":{
"__html":"Conditions and Comorbidities Associated With Increased Risk for Low Bone Mass and Osteoporosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"7d1b1e",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 45. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t45"
}
]
},
"Conditions and Comorbidities Associated With Increased Risk for Low Bone Mass and Osteoporosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"327a97",
"class":"col hd l",
"children":[
"Endocrine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef024b",
"class":"col hd l",
"children":[
"Gastrointestinal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20042c",
"class":"col hd l",
"children":[
"Hematologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42dab3",
"class":"col hd l",
"children":[
"Rheumatologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bd728",
"class":"col hd l",
"children":[
"Neurologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6311ae",
"class":"col hd l",
"children":[
"Other"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"517291",
"class":"cell txt l",
"children":[
"Anorexia nervosa"
]
},
" ",
{
"type":"p",
"hlId":"55f15a",
"class":"cell txt l",
"children":[
"Cushing syndrome"
]
},
" ",
{
"type":"p",
"hlId":"05159a",
"class":"cell txt l",
"children":[
"Diabetes mellitus"
]
},
" ",
{
"type":"p",
"hlId":"1bbbe9",
"class":"cell txt l",
"children":[
"Hyperparathyroidism"
]
},
" ",
{
"type":"p",
"hlId":"776b00",
"class":"cell txt l",
"children":[
"Hypogonadism (including Turner syndrome, Klinefelter syndrome)"
]
},
" ",
{
"type":"p",
"hlId":"3d6a7a",
"class":"cell txt l",
"children":[
"Thyrotoxicosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3492f",
"class":"cell txt l",
"children":[
"Bariatric surgery"
]
},
" ",
{
"type":"p",
"hlId":"6b2970",
"class":"cell txt l",
"children":[
"Celiac disease"
]
},
" ",
{
"type":"p",
"hlId":"271f14",
"class":"cell txt l",
"children":[
"Inflammatory bowel disease"
]
},
" ",
{
"type":"p",
"hlId":"233023",
"class":"cell txt l",
"children":[
"Malabsorption"
]
},
" ",
{
"type":"p",
"hlId":"64292c",
"class":"cell txt l",
"children":[
"Primary biliary cholangitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97fa04",
"class":"cell txt l",
"children":[
"Amyloidosis"
]
},
" ",
{
"type":"p",
"hlId":"46e89a",
"class":"cell txt l",
"children":[
"Systemic mastocytosis"
]
},
" ",
{
"type":"p",
"hlId":"ec0e62",
"class":"cell txt l",
"children":[
"Monoclonal gammopathies"
]
},
" ",
{
"type":"p",
"hlId":"8ea5c9",
"class":"cell txt l",
"children":[
"Multiple myeloma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d107e",
"class":"cell txt l",
"children":[
"Ankylosing spondylitis"
]
},
" ",
{
"type":"p",
"hlId":"a24b15",
"class":"cell txt l",
"children":[
"Rheumatoid arthritis"
]
},
" ",
{
"type":"p",
"hlId":"32ee95",
"class":"cell txt l",
"children":[
"Systemic lupus erythematosus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafb49",
"class":"cell txt l",
"children":[
"Multiple sclerosis"
]
},
" ",
{
"type":"p",
"hlId":"1a0cf5",
"class":"cell txt l",
"children":[
"Muscular dystrophy"
]
},
" ",
{
"type":"p",
"hlId":"a5db4b",
"class":"cell txt l",
"children":[
"Spinal cord injury with paralysis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d87ce",
"class":"cell txt l",
"children":[
"AIDS/HIV"
]
},
" ",
{
"type":"p",
"hlId":"1daad0",
"class":"cell txt l",
"children":[
"Chronic obstructive lung disease"
]
},
" ",
{
"type":"p",
"hlId":"6aaa1d",
"class":"cell txt l",
"children":[
"End-stage kidney disease"
]
},
" ",
{
"type":"p",
"hlId":"97e575",
"class":"cell txt l",
"children":[
"Idiopathic hypercalciuria"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_en_t46":{
"id":"mk19_b_en_t46",
"number":46,
"bookId":"en",
"title":{
"__html":"Recommendations for Measurement of Bone Mineral Density and Vertebral Imaging"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"bda58c",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 46. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t46"
}
]
},
"Recommendations for Measurement of Bone Mineral Density and Vertebral Imaging"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5ee8f0",
"class":"col hd l",
"children":[
"Bone Mineral Density Testing",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6ee1e",
"class":"cell txt l",
"children":[
"Women aged ≥65 years"
]
},
" ",
{
"type":"p",
"hlId":"f4b1b9",
"class":"cell txt l",
"children":[
"Men: Evidence is insufficient to assess benefits/harms of routine screening for osteoporosis",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20dd85",
"class":"cell txt l",
"children":[
"Postmenopausal women and men aged 50-69 years, based on risk-factor profile"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec6639",
"class":"cell txt l",
"children":[
"Fragility fracture, to determine degree of disease severity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cda400",
"class":"cell txt l",
"children":[
"Radiographic findings suggestive of osteoporosis or vertebral deformity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"50b8c3",
"class":"cell txt l",
"children":[
"Glucocorticoid therapy within 6 months of initiation for patients aged ≥40 years or for patients aged <40 years with osteoporotic fracture or risk factors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f26d26",
"class":"cell txt l",
"children":[
"Primary hyperparathyroidism",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9c7a68",
"class":"col hd l",
"children":[
"Vertebral Imaging",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"13dc25",
"class":"cell txt l",
"children":[
"Women aged ≥70 years and men aged ≥80 years if T-score at the spine, total hip, or femoral neck is ≤−1.0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f5269f",
"class":"cell txt l",
"children":[
"Women aged 65-69 years and men aged 75-79 years if T-score at the spine, total hip, or femoral neck is ≤−1.5"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9daba8",
"class":"cell txt l",
"children":[
"In postmenopausal women aged 50-64 years and men aged 50-69 years with the following risk factors:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ed4970",
"class":"cell txt li",
"children":[
"Fragility fractures"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94df8e",
"class":"cell txt li",
"children":[
"Historic height loss of 1.6 in (4 cm) or more from maximum lifetime height"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"40022d",
"class":"cell txt li",
"children":[
"Prospective height loss of 0.8 inches (2 cm) or more"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52ac07",
"class":"cell txt li",
"children":[
"Recent or ongoing long-term glucocorticoid treatment"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Bone mineral density testing should be performed at dual-energy x-ray absorptiometry facilities using accepted quality assurance measures."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"The U.S. National Osteoporosis Foundation recommends screening men aged ≥70 years, and the Endocrine Society recommends screening men aged ≥70 years, and men aged 50–69 years who have risk factors such as low body weight, fracture after age 50 years, or smoking."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Bone mineral density should be measured in the distal one-third of the radius in addition to hip and spine."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Vertebral imaging should be repeated when a new loss of height is noted or new back pain is reported."
]
]
},
"mk19_b_en_t47":{
"id":"mk19_b_en_t47",
"number":47,
"bookId":"en",
"title":{
"__html":"Diagnostic Studies to Evaluate for Secondary Causes of Osteoporosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"8c2bb3",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 47. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t47"
}
]
},
"Diagnostic Studies to Evaluate for Secondary Causes of Osteoporosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9c8a03",
"class":"col hd l",
"children":[
"Blood Testing",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c93ec1",
"class":"cell txt l",
"children":[
"Complete blood count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ddb06",
"class":"cell txt l",
"children":[
"Calcium, phosphorus, and magnesium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42ae22",
"class":"cell txt l",
"children":[
"Kidney function tests"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6e8c6",
"class":"cell txt l",
"children":[
"Liver enzymes including alkaline phosphatase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"84e552",
"class":"cell txt l",
"children":[
"Thyroid-stimulating hormone"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"73614d",
"class":"cell txt l",
"children":[
"25-hydroxyvitamin D"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80f470",
"class":"cell txt l",
"children":[
"Total testosterone (younger men)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d39dcd",
"class":"cell txt l",
"children":[
"Tryptase (systemic mastocytosis)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb9ec7",
"class":"col hd l",
"children":[
"Urine Testing",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c0aafc",
"class":"cell txt l",
"children":[
"24-h urinary calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"568390",
"class":"cell txt l",
"children":[
"Urinary free cortisol level"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Extent of testing should be influenced by clinical suspicion and severity of osteoporosis."
]
]
},
"mk19_b_en_t48":{
"id":"mk19_b_en_t48",
"number":48,
"bookId":"en",
"title":{
"__html":"FDA-Approved Medications for Osteoporosis Treatment and Prevention and Skeletal Sites of Proven Fracture Prevention With Treatment"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"42a786",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 48. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t48"
}
]
},
"FDA-Approved Medications for Osteoporosis Treatment and Prevention and Skeletal Sites of Proven Fracture Prevention With Treatment"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"c53b76",
"class":"col hd c",
"children":[
"Prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f120a",
"class":"col hd c",
"children":[
"Proven Fracture Prevention"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd c",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"916676",
"class":"col hd c",
"children":[
"PMO"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d4a43",
"class":"col hd c",
"children":[
"GIO"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e58fa",
"class":"col hd c",
"children":[
"Recurrent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"afcd5c",
"class":"col hd c",
"children":[
"Hip"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cbfcd7",
"class":"col hd c",
"children":[
"Vertebral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb807f",
"class":"col hd c",
"children":[
"Non-Vertebral"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3e417",
"class":"cell txt l",
"children":[
"Antiresorptive"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9e152",
"class":"cell txt l",
"children":[
"Bisphosphonates"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ecc4d5",
"class":"cell txt li",
"children":[
"Alendronate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c5e5e",
"class":"cell txt li",
"children":[
"Risedronate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"144c15",
"class":"cell txt li",
"children":[
"Ibandronate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c7297d",
"class":"cell txt li",
"children":[
"Zoledronic acid (intravenous)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9208da",
"class":"cell txt l",
"children":[
"Denosumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5daa0e",
"class":"cell txt l",
"children":[
"Raloxifene"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb7889",
"class":"cell txt l",
"children":[
"Conjugated estrogens/"
]
},
" ",
{
"type":"p",
"hlId":"3c27fd",
"class":"cell txt l",
"children":[
"bazedoxifene"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c714e2",
"class":"cell txt l",
"children":[
"Anabolic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34b8d7",
"class":"cell txt li",
"children":[
"Abaloparatide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e60647",
"class":"cell txt li",
"children":[
"Teriparatide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"699b4f",
"class":"cell txt li",
"children":[
"Mixed"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ed416",
"class":"cell txt li",
"children":[
"Romosozumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"206a42",
"class":"cell txt c",
"children":[
"√"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"GIO = glucocorticoid-induced osteoporosis; PMO = postmenopausal osteoporosis."
]
]
},
"mk19_b_en_t49":{
"id":"mk19_b_en_t49",
"number":49,
"bookId":"en",
"title":{
"__html":"Treatment of Vitamin D Deficiency"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a5f139",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 49. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t49"
}
]
},
"Treatment of Vitamin D Deficiency"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35b289",
"class":"col hd l",
"children":[
"Dose Required to Achieve Level >20 to 30 ng/dL (50-75 nmol/L)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b107fd",
"class":"cell txt l",
"children":[
"Bone, parathyroid or calcium disorders"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25f6f7",
"class":"cell txt l",
"children":[
"1000 to 2000 IU/day"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"233023",
"class":"cell txt l",
"children":[
"Malabsorption"
]
},
" ",
{
"type":"p",
"hlId":"002312",
"class":"cell txt l",
"children":[
"Chronic lack of sun exposure"
]
},
" ",
{
"type":"p",
"hlId":"3f81d4",
"class":"cell txt l",
"children":[
"BMI >40"
]
},
" ",
{
"type":"p",
"hlId":"549b50",
"class":"cell txt l",
"children":[
"Advanced liver disease"
]
},
" ",
{
"type":"p",
"hlId":"f22a95",
"class":"cell txt l",
"children":[
"Medications interfering with vitamin D metabolism (e.g., phenytoin and phenobarbital)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8bac1",
"class":"cell txt l",
"children":[
"1000 to 4000 IU/day"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"082048",
"class":"cell txt l",
"children":[
"Undetectable 25-hydroxyvitamin D"
]
},
" ",
{
"type":"p",
"hlId":"0f8247",
"class":"cell txt l",
"children":[
"Hypocalcemia"
]
},
" ",
{
"type":"p",
"hlId":"67c15d",
"class":"cell txt l",
"children":[
"Osteomalacia caused by vitamin D deficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e843f0",
"class":"cell txt l",
"children":[
"Loading dose of 50,000 IU/day of either vitamin D",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" (ergocalciferol) or vitamin D",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" (cholecalciferol) weekly for 8 weeks, then 1000 to 4000 IU/day"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}